S&P 500   4,269.80 (-0.10%)
DOW   33,859.97 (-0.35%)
QQQ   328.60 (+0.03%)
AAPL   173.78 (-0.44%)
MSFT   290.45 (-0.30%)
META   174.40 (-0.26%)
GOOGL   119.90 (+0.29%)
AMZN   142.04 (-0.04%)
TSLA   910.31 (-0.18%)
NVDA   186.65 (+1.80%)
NIO   19.82 (-1.29%)
BABA   90.38 (+0.68%)
AMD   100.27 (+2.04%)
MU   62.62 (+1.62%)
T   18.40 (-0.11%)
CGC   3.78 (-6.90%)
F   15.98 (-0.31%)
GE   79.03 (-1.11%)
DIS   122.16 (-0.53%)
AMC   20.12 (-5.81%)
PYPL   98.48 (-0.95%)
PFE   48.53 (-1.50%)
NFLX   244.88 (+1.55%)
S&P 500   4,269.80 (-0.10%)
DOW   33,859.97 (-0.35%)
QQQ   328.60 (+0.03%)
AAPL   173.78 (-0.44%)
MSFT   290.45 (-0.30%)
META   174.40 (-0.26%)
GOOGL   119.90 (+0.29%)
AMZN   142.04 (-0.04%)
TSLA   910.31 (-0.18%)
NVDA   186.65 (+1.80%)
NIO   19.82 (-1.29%)
BABA   90.38 (+0.68%)
AMD   100.27 (+2.04%)
MU   62.62 (+1.62%)
T   18.40 (-0.11%)
CGC   3.78 (-6.90%)
F   15.98 (-0.31%)
GE   79.03 (-1.11%)
DIS   122.16 (-0.53%)
AMC   20.12 (-5.81%)
PYPL   98.48 (-0.95%)
PFE   48.53 (-1.50%)
NFLX   244.88 (+1.55%)
S&P 500   4,269.80 (-0.10%)
DOW   33,859.97 (-0.35%)
QQQ   328.60 (+0.03%)
AAPL   173.78 (-0.44%)
MSFT   290.45 (-0.30%)
META   174.40 (-0.26%)
GOOGL   119.90 (+0.29%)
AMZN   142.04 (-0.04%)
TSLA   910.31 (-0.18%)
NVDA   186.65 (+1.80%)
NIO   19.82 (-1.29%)
BABA   90.38 (+0.68%)
AMD   100.27 (+2.04%)
MU   62.62 (+1.62%)
T   18.40 (-0.11%)
CGC   3.78 (-6.90%)
F   15.98 (-0.31%)
GE   79.03 (-1.11%)
DIS   122.16 (-0.53%)
AMC   20.12 (-5.81%)
PYPL   98.48 (-0.95%)
PFE   48.53 (-1.50%)
NFLX   244.88 (+1.55%)
S&P 500   4,269.80 (-0.10%)
DOW   33,859.97 (-0.35%)
QQQ   328.60 (+0.03%)
AAPL   173.78 (-0.44%)
MSFT   290.45 (-0.30%)
META   174.40 (-0.26%)
GOOGL   119.90 (+0.29%)
AMZN   142.04 (-0.04%)
TSLA   910.31 (-0.18%)
NVDA   186.65 (+1.80%)
NIO   19.82 (-1.29%)
BABA   90.38 (+0.68%)
AMD   100.27 (+2.04%)
MU   62.62 (+1.62%)
T   18.40 (-0.11%)
CGC   3.78 (-6.90%)
F   15.98 (-0.31%)
GE   79.03 (-1.11%)
DIS   122.16 (-0.53%)
AMC   20.12 (-5.81%)
PYPL   98.48 (-0.95%)
PFE   48.53 (-1.50%)
NFLX   244.88 (+1.55%)
TSE:ONC

Oncolytics Biotech - ONC Stock Forecast, Price & News

C$1.62
0.00 (0.00%)
(As of 08/18/2022 12:45 PM ET)
Add
Compare
Today's Range
C$1.62
C$1.64
50-Day Range
C$1.12
C$1.72
52-Week Range
C$1.06
C$2.96
Volume
2,885 shs
Average Volume
63,054 shs
Market Capitalization
C$93.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
C$15.00

Oncolytics Biotech MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
825.9% Upside
C$15.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of Oncolytics Biotech in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
C$17,727 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.59 out of 5 stars

ONC stock logo

About Oncolytics Biotech (TSE:ONC) Stock

Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Oncolytics Biotech Stock Performance

TSE:ONC opened at C$1.62 on Thursday. Oncolytics Biotech has a twelve month low of C$1.06 and a twelve month high of C$2.96. The stock has a 50-day moving average of C$1.39 and a 200 day moving average of C$1.72. The company has a current ratio of 15.49, a quick ratio of 13.38 and a debt-to-equity ratio of 1.70. The stock has a market capitalization of C$93.74 million and a price-to-earnings ratio of -3.36.

Receive ONC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncolytics Biotech and its competitors with MarketBeat's FREE daily newsletter.

ONC Stock News Headlines

Oncolytics Biotech Inc. (ONCY)
Oncolytics Biotech (ONC) Set to Announce Earnings on Thursday
See More Headlines
Receive ONC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncolytics Biotech and its competitors with MarketBeat's FREE daily newsletter.

ONC Company Calendar

Today
8/18/2022
Next Earnings (Estimated)
11/04/2022

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
26
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
C$15.00
High Stock Price Forecast
C$15.00
Low Stock Price Forecast
C$15.00
Forecasted Upside/Downside
+825.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
C$0.56 per share
Book Value
C$0.53 per share

Miscellaneous

Free Float
N/A
Market Cap
C$93.74 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Dr. Matthew C. Coffey M.B.A.
    Ph.D., Pres, CEO & Director
  • Mr. Kirk J. Look C.A.
    CA, Chief Financial Officer
  • Mr. Andrew R. de Guttadauro (Age 55)
    Global Head of Bus. Devel. & Pres of Oncolytics Biotech (U.S.) Inc
    Comp: $558.94k
  • Dr. Thomas C. Heineman M.D.
    Ph.D., Chief Medical Officer
  • Ms. Allison Hagerman P.Eng.
    P.M.P., VP of Product Devel.
  • Jon Patton
    Director of Investor Relations & Communication
  • Dr. Grey Wilkinson Ph.D.
    Scientist of Translational Medicine
  • Mr. John Mark Lievonen F.C.A.
    FCA, Consultant
  • Dr. Daniel Douglas Von Hoff F.A.C.P. (Age 74)
    FACP, M.D., Consultant













ONC Stock - Frequently Asked Questions

Should I buy or sell Oncolytics Biotech stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oncolytics Biotech in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ONC shares.
View ONC analyst ratings
or view top-rated stocks.

What is Oncolytics Biotech's stock price forecast for 2022?

2 analysts have issued 12-month price targets for Oncolytics Biotech's shares. Their ONC share price forecasts range from C$15.00 to C$15.00. On average, they expect the company's share price to reach C$15.00 in the next year. This suggests a possible upside of 825.9% from the stock's current price.
View analysts price targets for ONC
or view top-rated stocks among Wall Street analysts.

How have ONC shares performed in 2022?

Oncolytics Biotech's stock was trading at C$1.75 at the start of the year. Since then, ONC shares have decreased by 7.4% and is now trading at C$1.62.
View the best growth stocks for 2022 here
.

When is Oncolytics Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, November 4th 2022.
View our ONC earnings forecast
.

What other stocks do shareholders of Oncolytics Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oncolytics Biotech investors own include Oncolytics Biotech (ONCY), (ONCYF) (ONCYF), Resverlogix (RVX), Ballard Power Systems (BLDP), ProMetic Life Sciences (PLI), Bombardier (BDRBF), Birchcliff Energy (BIR), Enbridge (ENB) and First Majestic Silver (FR).

What is Oncolytics Biotech's stock symbol?

Oncolytics Biotech trades on the Toronto Stock Exchange (TSX) under the ticker symbol "ONC."

How do I buy shares of Oncolytics Biotech?

Shares of ONC stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Oncolytics Biotech's stock price today?

One share of ONC stock can currently be purchased for approximately C$1.62.

How much money does Oncolytics Biotech make?

Oncolytics Biotech (TSE:ONC) has a market capitalization of C$93.74 million.

How can I contact Oncolytics Biotech?

Oncolytics Biotech's mailing address is 1167 Kensington Cres Nw Suite 210 Calgary Alberta Canada T2n 1X7, CALGARY, AB 00000, Canada. The official website for the company is www.oncolyticsbiotech.com. The company can be reached via phone at +1-403-6707380.

This page (TSE:ONC) was last updated on 8/18/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.